Sumitomo Mitsui Trust Group Inc. Grows Position in IQVIA Holdings Inc. (NYSE:IQV)

Sumitomo Mitsui Trust Group Inc. raised its holdings in IQVIA Holdings Inc. (NYSE:IQV) by 2.6% during the 4th quarter, according to the company in its most recent filing with the Securities & Exchange Commission. The institutional investor owned 1,049,912 shares of the medical research company’s stock after acquiring an additional 26,648 shares during the period. Sumitomo Mitsui Trust Group Inc.’s holdings in IQVIA were worth $206,318,000 at the end of the most recent reporting period.

Several other institutional investors and hedge funds have also recently modified their holdings of IQV. Sanctuary Advisors LLC purchased a new stake in shares of IQVIA in the 2nd quarter valued at about $803,000. Czech National Bank raised its holdings in shares of IQVIA by 1.6% during the 3rd quarter. Czech National Bank now owns 35,279 shares of the medical research company’s stock valued at $8,360,000 after buying an additional 559 shares in the last quarter. GAMMA Investing LLC raised its holdings in shares of IQVIA by 36.1% during the 3rd quarter. GAMMA Investing LLC now owns 1,101 shares of the medical research company’s stock valued at $261,000 after buying an additional 292 shares in the last quarter. Wedmont Private Capital raised its holdings in shares of IQVIA by 9.5% during the 3rd quarter. Wedmont Private Capital now owns 2,042 shares of the medical research company’s stock valued at $460,000 after buying an additional 178 shares in the last quarter. Finally, Bruce G. Allen Investments LLC raised its holdings in shares of IQVIA by 1,013.6% during the 3rd quarter. Bruce G. Allen Investments LLC now owns 245 shares of the medical research company’s stock valued at $58,000 after buying an additional 223 shares in the last quarter. Hedge funds and other institutional investors own 89.62% of the company’s stock.

Insider Transactions at IQVIA

In other IQVIA news, Director John G. Danhakl purchased 1,275 shares of the firm’s stock in a transaction dated Tuesday, December 3rd. The stock was purchased at an average price of $200.58 per share, for a total transaction of $255,739.50. Following the completion of the purchase, the director now directly owns 1,275 shares of the company’s stock, valued at $255,739.50. This trade represents a ∞ increase in their ownership of the stock. The acquisition was disclosed in a legal filing with the SEC, which can be accessed through the SEC website. Company insiders own 1.60% of the company’s stock.

IQVIA Stock Down 0.9 %

Shares of NYSE:IQV opened at $208.13 on Friday. The stock has a fifty day simple moving average of $200.53 and a two-hundred day simple moving average of $219.80. The stock has a market capitalization of $37.78 billion, a price-to-earnings ratio of 27.31, a PEG ratio of 2.15 and a beta of 1.48. IQVIA Holdings Inc. has a 12-month low of $187.62 and a 12-month high of $261.73. The company has a current ratio of 0.81, a quick ratio of 0.81 and a debt-to-equity ratio of 1.76.

IQVIA (NYSE:IQV) last announced its quarterly earnings data on Thursday, February 6th. The medical research company reported $2.90 earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of $3.11 by ($0.21). IQVIA had a net margin of 9.17% and a return on equity of 28.17%. On average, research analysts anticipate that IQVIA Holdings Inc. will post 10.18 earnings per share for the current fiscal year.

Wall Street Analysts Forecast Growth

A number of equities analysts recently weighed in on IQV shares. The Goldman Sachs Group decreased their price objective on IQVIA from $280.00 to $250.00 and set a “buy” rating on the stock in a report on Friday, November 1st. StockNews.com lowered IQVIA from a “buy” rating to a “hold” rating in a research report on Thursday, November 28th. BTIG Research lowered IQVIA from a “buy” rating to a “neutral” rating in a research report on Monday, February 3rd. Stifel Nicolaus reduced their price target on IQVIA from $273.00 to $261.00 and set a “buy” rating on the stock in a research report on Friday. Finally, Deutsche Bank Aktiengesellschaft reduced their price target on IQVIA from $270.00 to $265.00 and set a “buy” rating on the stock in a research report on Friday, November 1st. Five research analysts have rated the stock with a hold rating, seventeen have given a buy rating and one has issued a strong buy rating to the company’s stock. According to MarketBeat.com, the company currently has an average rating of “Moderate Buy” and an average price target of $252.39.

IQVIA Profile

IQVIA Holdings Inc engages in the provision of advanced analytics, technology solutions, and clinical research services to the life sciences industry in the Americas, Europe, Africa, and the Asia-Pacific. It operates through three segments: Technology & Analytics Solutions, Research & Development Solutions, and Contract Sales & Medical Solutions.